A long-time leader in the respiratory field, Boehringer Ingelheim GMBH has teamed up with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Oxford BioMedica PLC to develop a long-term treatment aimed at correcting the underlying genetic causes of the devastating lung disease.
Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy
The German major is making its first foray into gene therapy and is looking to license a new viral vector-based product that could create a new therapeutic pathway for CF patients, regardless of their mutations.
More from Rare Diseases
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from Scrip
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?